🧬 Aging Wiki

lpa

Properties1
aliasesLPA gene, apolipoprotein(a), apo(a), APOA, lipoprotein(a), Lp(a)

17 min read

Lp(a) — Lipoprotein(a) / apo(a)

Lipoprotein(a) [Lp(a)] is a genetically determined, highly atherogenic and prothrombotic lipoprotein particle that is causally associated with ASCVD independent of LDL cholesterol, via Mendelian randomization 12. On a per-particle basis, Lp(a) is ~6.6-fold more atherogenic than LDL (95% CI: 5.1–8.8) 3. Plasma Lp(a) concentration is largely heritable (~70–90%), diet- and exercise-resistant, and statin-resistant — distinguishing it sharply from other atherogenic lipoproteins. The LPA gene encodes apo(a) (apolipoprotein(a)), the particle’s unique structural component; the assembled circulating particle = apo(a) covalently linked to an LDL-like particle (one ApoB-100 + cholesterol-ester core) via a single disulfide bond. Three Phase 3 cardiovascular-outcomes trials are ongoing for RNA-targeted Lp(a)-lowering agents.

Clinical relevance: Lp(a) is increasingly used as a statin-initiation modifier — a result >50 mg/dL is often treated as an indication to initiate a statin regardless of LDL-C or ApoB level.

Identity

  • UniProt: P08519 (APOA_HUMAN) — Swiss-Prot reviewed; confirmed via UniProt REST API 2026-05-09
  • Gene: LPA (chromosome 6q26–q27)
  • NCBI Gene: 4018
  • HGNC: 6667 (symbol: LPA)
  • Ensembl: ENSG00000198670
  • Protein length: 2,040 amino acids (apo(a) precursor including 19-aa signal peptide)
  • Mouse ortholog: none — mice lack a functional Lpa gene with full kringle-repeat architecture. Lp(a) biology cannot be studied in standard mouse models. This is a major translational bottleneck. needs-human-replication applies narrowly to mechanism studies; epidemiologic and genetic causality are well-established in humans via MR.

Naming convention on this page: LPA = gene; apo(a) = protein (apolipoprotein(a), the gene product); Lp(a) = assembled circulating particle = apo(a) + ApoB-100 + lipid core.

Gene and protein structure

LPA evolved from plasminogen gene duplication

LPA arose by tandem duplication and divergence of the plasminogen gene (PLG) on chromosome 6 4. Apo(a) is structurally homologous to plasminogen but has lost fibrinolytic activity — its serine-protease domain is catalytically inactive (the active-site serine is mutated). This evolutionary history is the molecular basis for apo(a)‘s competition with plasminogen for fibrin and lysine-binding sites on fibrin clots — directly explaining Lp(a)‘s prothrombotic mechanism.

Kringle domain architecture

Apo(a) is composed almost entirely of kringle domains — triple-disulfide-bridge globular folds originally described in plasminogen:

DomainCopiesNotes
Kringle IV type 1 (KIV-1)1Unique; distinguishes apo(a) from plasminogen
Kringle IV type 2 (KIV-2)1 to >40 copies (CNV)Copy-number variable; main genetic determinant of Lp(a) size and plasma level
Kringle IV types 3–10 (KIV-3 to KIV-10)1 eachFixed; KIV-10 contains the strong-lysine-binding site that preferentially binds OxPL
Kringle V (KV)1Structural
Protease domain1Serine-protease fold; catalytically inactive (Ser → Arg active-site mutation)

KIV-2 copy-number variation (CNV) is the primary genetic determinant of plasma Lp(a) levels. More KIV-2 repeats → larger apo(a) → slower hepatic secretion → lower plasma Lp(a). Fewer KIV-2 repeats → smaller, more efficiently secreted apo(a) → higher plasma Lp(a) 4. This inverse relationship is why Lp(a) genetic epidemiology uses SNPs in/around KIV-2 (rs10455872, rs3798220) as instruments for MR analyses.

Disulfide linkage to ApoB-100

The assembled Lp(a) particle forms via a single disulfide bond between a cysteine residue in apo(a)‘s KIV-9 domain and Cys4326 of ApoB-100 on an LDL-like particle. The LDL core (cholesterol ester, triglyceride) and the full ApoB-100 molecule are retained. Each Lp(a) particle therefore contains exactly one apo(a) and one ApoB-100 — meaning Lp(a) particles are captured by the standard ApoB assay, but the ApoB-100 on Lp(a) particles is not distinguished from LDL-ApoB-100. This is why Lp(a) must be measured separately: the ApoB assay counts Lp(a) particles equally with LDL particles, but since Lp(a) is ~6.6× more atherogenic per particle, the ApoB number underestimates total atherogenic risk for individuals with elevated Lp(a) — the higher-risk Lp(a)-ApoB particles are blended indistinguishably into the same ApoB total as lower-risk LDL-ApoB particles 5.

Epidemiology and clinical thresholds

Plasma Lp(a) has a highly right-skewed distribution in populations. Approximately 20% of Caucasian-ancestry individuals have Lp(a) >50 mg/dL 6. The threshold for clinical significance is less than perfectly defined across guidelines, but the following tiered framework is used across major societies (ESC, AHA/ACC):

Levelmg/dLnmol/L (approx)Clinical significance
Low<30<75No elevated risk
Borderline30–5075–125Modest incremental risk; consider in context
High50–125125–312Elevated risk; guideline-indicated statin escalation trigger
Very high>125>312Major independent ASCVD risk factor; consider aggressive LDL lowering + lipoprotein apheresis candidacy

Units note: mg/dL and nmol/L are NOT interconvertible by a fixed factor because apo(a) isoform size varies. Smaller isoforms have higher particle count (nmol/L) per unit mass (mg/dL). Modern guidelines increasingly prefer nmol/L as it measures particle number. The rough approximation nmol/L ≈ 2.5 × mg/dL is isoform-size-dependent and should not be treated as exact. dose-response-unclear regarding whether nmol/L thresholds should be used instead of mg/dL in clinical practice; guideline convergence is ongoing.

Decision threshold: An Lp(a) >50 mg/dL is commonly treated as a trigger to initiate a statin regardless of LDL-C or ApoB level. This threshold aligns with ESC 2019 guidelines, which designate ≥50 mg/dL (≥125 nmol/L) as “high” Lp(a).

Heritability and genetic architecture

Plasma Lp(a) concentration is ~70–90% heritable, making it the most genetically determined major cardiovascular risk biomarker 4. This heritability is explained primarily by:

  1. KIV-2 CNV — explains ~30–70% of population Lp(a) variance; dominantly inversely correlated with Lp(a) concentration
  2. LPA promoter variants (e.g., rs10455872, rs3798220) — SNPs used as MR instruments; strong associations with Lp(a) concentration
  3. Other LPA variants — rare coding variants modifying apo(a) secretion efficiency

This high heritability has important clinical implications: diet, exercise, weight loss, and most lipid-lowering drugs have minimal impact on plasma Lp(a) concentration. Lp(a) is physiologically “set” by genetics from birth.

Mendelian randomization: causal evidence for ASCVD

Lp(a) has strong MR-validated causal evidence for multiple ASCVD endpoints:

Myocardial infarction: Kamstrup et al. (JAMA, 2009) performed the first prospective MR study of Lp(a) and MI across three Danish cohorts (CCHS, CGPS, CIHDS; total n≈40,486). Using the LPA KIV-2 repeat-size polymorphism as the genetic instrument, genetically elevated Lp(a) was causally associated with MI risk: HR 1.22 (95% CI: 1.09–1.37) per doubling of Lp(a) concentration by instrumental variable analysis 1. This established causality — not merely association — for Lp(a) and MI.

Coronary disease and therapeutic implications: Burgess, Ference et al. (JAMA Cardiology, 2018) performed MR analysis using LPA SNPs in the CHD Exome+ Consortium (n=48,333 individual participant data from 5 studies, including 20,793 with CHD) with external validation in CARDIoGRAMplusC4D summarized data (62,240 CHD cases + 127,299 controls). Key quantitative finding: a 101.5 mg/dL reduction in Lp(a) (95% CI: 71.0–137.0) would be required to achieve a clinically meaningful benefit equivalent to a 38.67 mg/dL LDL-C reduction — helping define the magnitude of Lp(a) reduction needed from emerging therapies to achieve cardiovascular outcomes benefit 2.

Per-particle atherogenicity: Björnson et al. (JACC, 2024) used ApoB-based genetic analysis in 502,413 UK Biobank participants to quantify the per-particle atherogenicity of Lp(a) vs LDL. MR-derived OR for CHD per 50 nmol/L higher Lp(a)-apoB was 1.28 (95% CI: 1.24–1.33) vs 1.04 (95% CI: 1.03–1.05) for LDL-apoB. From these data, Lp(a) atherogenicity is estimated at approximately 6.6-fold greater (95% CI: 5.1–8.8) than LDL on a per-particle basis 3. This finding reinforces why even modest Lp(a) concentrations can be clinically significant in individuals with otherwise-optimal LDL.

Additive benefit with LDL-C lowering: Wang et al. (Int J Epidemiology, 2025) factorial MR showed that combined Lp(a) lowering and LDL-C lowering provides additive cardiovascular risk reduction with no evidence for departure from additivity — supporting concurrent aggressive lipid lowering in high-Lp(a) individuals [

Atherosclerotic stenosis vs venous thrombosis: Kamstrup, Tybjærg-Hansen, Nordestgaard (ATVB, 2012) used MR to show Lp(a) is causally associated with atherosclerotic stenosis (HR 1.12–1.21) but not with venous thrombosis (HR ~1.02–1.04) — the prothrombotic mechanism of Lp(a) acts in the arterial context (via fibrinolysis inhibition) rather than the venous clotting cascade 7.

DimensionStatusNotes
Pathway conserved in humans?yes — Lp(a) biology is essentially human-specificStandard mice lack functional Lpa; no murine model
Phenotype conserved in humans?yesAll causal evidence is from human genetic + epidemiological studies
Replicated in humans?yesMultiple large-cohort MR studies, consistent findings

Mechanisms of atherogenicity and prothrombosis

Lp(a) pathogenicity operates through at least three reinforcing mechanisms:

1. LDL-like cholesterol delivery

As an ApoB-100-containing particle, Lp(a) behaves like a modified LDL in the vascular wall — binding to arterial wall proteoglycans (decorin, biglycan via apo(a)‘s lysine-binding sites), crossing the endothelium, becoming trapped in the subintimal space, and contributing to foam-cell formation and plaque progression. Because Lp(a) is ~6× more atherogenic per particle than LDL, its contribution to atherogenic particle burden is disproportionate to its mass 38.

2. Oxidized phospholipid (OxPL) carrier

Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL) in human plasma. The apo(a) KIV-10 domain contains a strong-lysine-binding site that preferentially binds OxPL moieties generated by lipid oxidation. OxPL carried by Lp(a) trigger vascular inflammation: activating endothelial cells (MCP-1 secretion, monocyte chemotaxis), promoting monocyte adhesion, stimulating macrophage-derived IL-8 production (promotes neutrophil infiltration), and driving foam-cell formation. Plasma OxPL-apoB (a surrogate for Lp(a)-carried OxPL) strongly predicts cardiovascular events independent of Lp(a) mass 8. no-mechanism — the exact molecular cascade from KIV-10/OxPL binding to downstream inflammatory activation is incompletely resolved.

3. Prothrombotic: competitive inhibition of plasminogen

Due to its structural homology to plasminogen (evolutionary gene duplication of PLG), apo(a) competes with plasminogen for fibrin-binding sites and lysine residues on fibrin clots. By displacing plasminogen from fibrin, apo(a) impairs tissue plasminogen activator (t-PA)-mediated fibrinolysis — the clot-dissolving mechanism. This impaired fibrinolysis is hypothesized to increase the risk of arterial thrombosis superimposed on atherosclerotic plaques, and may be particularly relevant for calcific aortic valve stenosis pathogenesis 86. Mechanistic caveat: MR evidence (Kamstrup 2012) argues against Lp(a) causing venous thrombosis, suggesting the prothrombotic effect is arterial context-dependent 7. contradictory-evidence between the molecular inhibition-of-fibrinolysis mechanism and the MR finding that Lp(a) doesn’t cause VTE.

Comparison to LDL — why Lp(a) must be measured separately

FeatureLDLLp(a)
ApoB contentOne ApoB-100 per particleOne ApoB-100 per particle (included in ApoB assay)
Unique structural proteinNoneApo(a)
Heritability~50–60%~70–90%
Diet/exercise modifiabilityModerate (20–30% LDL-C reduction possible)Minimal (<5%)
Statin response~30–50% LDL-C reductionMinimal or slight increase (see below)
Per-particle atherogenicityReference (1×)~6.6× greater 3
MR-validated ASCVD causalityyesyes
Captured by standard ApoB testyesyes (included in ApoB total, not separated)

Key point: A person with optimal ApoB (e.g., 60 mg/dL) but Lp(a) of 100 mg/dL is at meaningfully higher ASCVD risk than their ApoB number implies. Lp(a)-ApoB-100 particles are counted in the total ApoB but cannot be distinguished without a separate Lp(a) assay. For individuals with elevated Lp(a), total ApoB underestimates the problem because the Lp(a) particles (more atherogenic per particle) are blended with regular LDL particles. This is why Lp(a) measurement is additive to ApoB testing, not redundant with it.

Therapeutic landscape

What does NOT work

  • Diet and exercise: Minimal to no effect on plasma Lp(a). Lifestyle modification alone cannot meaningfully lower Lp(a) 6.
  • Statins: Statins minimally affect Lp(a) and some studies report a modest increase (5–15%) in Lp(a) with high-intensity statin therapy. Statins remain indicated in high-Lp(a) patients to lower non-Lp(a) atherogenic particles (LDL-C, VLDL), but they do not address Lp(a) directly.
  • Ezetimibe: Minimal effect on Lp(a).

Partial effect: PCSK9 inhibitors (~25% reduction)

Evolocumab and alirocumab (PCSK9 inhibitors, FDA-approved) reduce Lp(a) by approximately 25–30% on top of statin therapy — a secondary effect beyond their primary mechanism of upregulating LDLR-mediated LDL clearance. This Lp(a) reduction is clinically meaningful for patients in the borderline range but insufficient for patients with very high Lp(a). See pcsk9 for mechanistic detail 9.

Historical: Niacin (~25% reduction, discredited for outcomes)

Niacin reduces Lp(a) by ~25–30%. However, the AIM-HIGH (2011) and HPS2-THRIVE (2013) cardiovascular outcomes trials showed no benefit of niacin on top of statin therapy for major MACE — despite niacin lowering Lp(a), LDL-C, and triglycerides. Niacin is no longer recommended for cardiovascular prevention by FDA. The failure may reflect insufficient magnitude of Lp(a) reduction or off-target harms obscuring benefit. contradictory-evidence — the biochemical response (Lp(a) reduction) and the outcomes-trial results diverge; outcome-neutral finding for niacin does not rule out larger Lp(a) reductions being beneficial (see pelacarsen/olpasiran below).

Lipoprotein apheresis

Mechanical extracorporeal removal of LDL and Lp(a) from plasma. Acutely reduces Lp(a) by 60–75%. FDA-approved for patients with LDL-C >300 mg/dL (or >200 mg/dL on maximum tolerated drug therapy) and established ASCVD, or Lp(a) >60 mg/dL with progressive CAD. Logistically demanding (biweekly infusions); used in refractory high-Lp(a) cases. No large RCT demonstrating outcomes benefit in Lp(a)-specific indication. needs-human-replication for Lp(a)-specific outcomes benefit.

Emerging RNA-targeted therapies (Phase 3 outcomes trials ongoing)

Three RNA-targeting agents have produced dramatic Lp(a) reductions and are now in Phase 3 outcomes trials. The network meta-analysis by Wu et al. (Pharmacological Research, 2026) of 25 RCTs (n=7,715) synthesized the efficacy data 10:

AgentClassFrequencyLp(a) reductionTrialStatus
Pelacarsen (TQJ230)Antisense oligonucleotide (ASO) targeting LPA mRNAMonthly SC injection~54% (Wu 2026 meta-analysis)Lp(a)HORIZON (ASCVD secondary prevention; n~8,300; 4–5 yr readout)Phase 3, ongoing
OlpasiransiRNA targeting LPA mRNAQuarterly SC injection~92% (Wu 2026)OCEAN(a)-OutcomesPhase 3, ongoing
ZerlasiransiRNAQuarterly SC injection~81% (Wu 2026)Phase 3Ongoing
Lepodisiran (Lilly)siRNAQuarterly SC injectionPhase 2 data positivePhase 3 launchingPlanned
Muvalaplin (Lilly)Oral small molecule disrupting apo(a)–ApoB-100 disulfide-link formationDaily oral~65–77% (Wu 2026)Phase 2 completed; Phase 3 pendingPhase 2 done

Druggability tier = 2 rationale (aging context): No FDA-approved Lp(a)-specific drug exists as of 2026-05-09. Multiple Phase 3 cardiovascular-outcomes trials are actively recruiting or ongoing. The magnitude of Lp(a) reduction (>80–92% with siRNA) may be sufficient to demonstrate the outcomes benefit that niacin’s ~25% reduction failed to achieve. Tier would upgrade to 1 upon Phase 3 trial success.

Critical question: The Burgess/Ference 2018 MR analysis suggested that ~100 mg/dL Lp(a) reduction is needed to achieve benefit equivalent to ~39 mg/dL LDL-C reduction. Pelacarsen (~54%) may not achieve sufficient reduction in many patients; siRNA agents with ~80–92% reduction are better positioned. Whether any specific level of Lp(a) reduction translates to cardiovascular benefit in outcomes trials is the central open question 2.

Muvalaplin is mechanistically distinct: it is an oral small molecule that disrupts the protein-protein interaction between apo(a) and ApoB-100 during particle assembly in the liver — preventing Lp(a) particle formation rather than suppressing LPA mRNA. Phase 2 results showed ~65–77% Lp(a) reduction; oral dosing is a practical advantage if outcomes trials succeed 9.

Aging relevance

Lp(a) is atherogenic from birth: because plasma Lp(a) is genetically set and does not change substantially with age, individuals with elevated Lp(a) accumulate decades of excess atherogenic particle exposure. The cumulative exposure model for ASCVD (see apob for the parallel LDL argument) applies with particular force to Lp(a): by age 50–60, an individual with Lp(a) >100 mg/dL will have sustained 4–6 decades of 6.6× per-particle atherogenicity vs LDL. This is the basis for guidelines recommending early Lp(a) testing (once in a lifetime screening), especially given emerging Phase 3 trials that may provide actionable pharmacotherapy.

There is no direct evidence linking Lp(a) to hallmarks of aging beyond atherosclerosis-mediated chronic-inflammation and endothelial signaling disruption (altered-intercellular-communication). Lp(a)‘s SASP-parallel effect — OxPL-driven macrophage activation, IL-8 release — represents a chronically active inflammatory signal originating from a genetically invariant particle burden. unsourced — no study directly linking Lp(a) to canonical hallmark biology (telomere attrition, senescent cell burden, etc.) is available from current evidence.

Pathway context

Lp(a) exists within lipoprotein-metabolism as the “rogue” sub-pathway — a particle assembled in the liver, secreted into plasma, not cleared efficiently by ldlr (because apo(a) sterically hinders the ApoB-100 receptor-binding domain), and not remodeled by peripheral lipolysis like standard VLDL→IDL→LDL. Lp(a) is effectively a permanently elevated atherogenic particle burden for individuals with elevated plasma concentrations.

Key relationships:

  • apob — ApoB-100 provides the LDL-like lipid core of Lp(a); ApoB assay includes Lp(a)-ApoB
  • ldlr — Lp(a) is poorly cleared by LDLR (apo(a) interferes with ApoB site B → LDLR interaction); PCSK9 inhibition modestly lowers Lp(a) by freeing up LDLR
  • pcsk9 — PCSK9 inhibitors reduce Lp(a) ~25%; mechanism involves improved Lp(a) clearance via non-LDLR receptors
  • atherosclerosis — Lp(a) is a direct causal driver via cholesterol delivery, OxPL-inflammation, and impaired fibrinolysis
  • familial-hypercholesterolemia — FH patients often have co-elevated LDL and Lp(a); synergistically very high ASCVD risk

Limitations and gaps

  • No mouse model. Standard mice lack functional Lpa; all mechanistic data come from human genetic epidemiology, in vitro studies, and transgenic models that incompletely recapitulate human Lp(a) biology. needs-human-replication for mechanistic claims.
  • nmol/L vs mg/dL conversion. No fixed conversion factor; isoform size matters. Clinical labs differ in which unit they report. If a panel reports in nmol/L, recalibrate decision thresholds accordingly (>125 nmol/L = high; >312 nmol/L = very high).
  • Phase 3 outcomes trials still pending. None of pelacarsen (Lp(a)HORIZON) or olpasiran (OCEAN(a)-Outcomes) has reported outcomes data as of 2026-05-09. The therapeutic landscape could change substantially with trial readouts.
  • OxPL mechanistic cascade. The exact downstream signaling from KIV-10/OxPL binding to vascular inflammation is incompletely characterized. no-mechanism
  • GTEx aging expression data. gtex-aging-correlation: null — LPA hepatic expression trajectory with age not yet pulled.
  • KIV-2 CNV page absent. [[lpa-kiv2-cnv]] referenced in caused-by: is a forward reference (stub not yet created). The CNV is the dominant genetic driver of Lp(a) levels; a dedicated page would support Dataview queries on copy-number variants.
  • Niacin outcomes-trial discordance. The divergence between niacin’s biochemical Lp(a) reduction and lack of CV outcomes benefit is not fully explained. Pending Lp(a)-specific outcomes trials (pelacarsen, olpasiran) will provide the definitive test of whether the MR-predicted benefit is achievable pharmacologically. contradictory-evidence

Footnotes

Footnotes

  1. doi:10.1001/jama.2009.801 · Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG · JAMA 2009 · mendelian-randomization · three Danish cohorts: CCHS n=8,637 (prospective, 16-yr follow-up, 599 MI events) + CGPS n=29,388 + CIHDS n=2,461; total n≈40,486 · instrument: KIV-2 repeat-size polymorphism (explains 21–27% Lp(a) variance) · model: human · HR 1.22 (95% CI 1.09–1.37) per doubling of Lp(a) by instrumental variable analysis; established causality for Lp(a) → MI · 1,269 citations; closed-access (not_oa); verified against PubMed abstract (PMID 19509380) ↩ ↩2

  2. doi:10.1001/jamacardio.2018.1470 · Burgess S, Ference BA et al. · JAMA Cardiology 2018 · mendelian-randomization · primary analysis: n=48,333 individual participant data from 5 CHD Exome+ Consortium studies (20,793 CHD cases); external validation: CARDIoGRAMplusC4D summarized data (62,240 CHD + 127,299 controls); LPA genetic score: 43 conditionally selected variants · model: human · 101.5 mg/dL Lp(a) reduction (95% CI 71.0–137.0) needed to equal benefit of 38.67 mg/dL LDL-C reduction; CHD risk proportional to absolute (not proportional) Lp(a) change · 627 citations; locally available at ↩ ↩2 ↩3

  3. doi:10.1016/j.jacc.2023.10.039 · Björnson E, Adiels M, Taskinen M-R et al. · Journal of the American College of Cardiology 2024 · mendelian-randomization · n=502,413 UK Biobank (54.4% female); Lp(a) cluster: 107 SNPs; LDL cluster: 143 SNPs · model: human · MR OR for CHD per 50 nmol/L higher Lp(a)-apoB: 1.28 (95% CI 1.24–1.33) vs LDL-apoB: 1.04 (95% CI 1.03–1.05); point estimate of Lp(a) atherogenicity 6.6-fold greater than LDL per particle (95% CI 5.1–8.8) · 167 citations; locally available at ↩ ↩2 ↩3 ↩4

  4. doi:10.1194/jlr.r067314 · Schmidt K, Noureen A, Kronenberg F, Utermann G · Journal of Lipid Research 2016 · review · n=N/A · model: human · LPA gene structure, KIV-2 CNV, heritability (~70–90%), plasminogen gene-duplication origin; canonical structural reference · 643 citations; locally available at ↩ ↩2 ↩3

  5. doi:10.1001/jamacardio.2019.3780 · Sniderman AD, Thanassoulis G et al. · JAMA Cardiology 2019 · review · Lp(a)-ApoB inclusion in total ApoB assay; see apob page for full verification notes ↩

  6. doi:10.1093/clinchem/hvaa247 · Kamstrup PR · Clinical Chemistry 2021 · review · n=N/A · model: human · 2–3-fold Lp(a)-associated MI risk; population epidemiology, MR, and clinical threshold synthesis · 230 citations; download pending (bronze OA) ↩ ↩2 ↩3

  7. doi:10.1161/atvbaha.112.248765 · Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG · Arteriosclerosis, Thrombosis, and Vascular Biology 2012 · mendelian-randomization · Copenhagen cohorts · model: human · Lp(a) causally associated with atherosclerotic stenosis (HR 1.12–1.21) but not venous thrombosis (HR ~1.02–1.04) · 184 citations; closed-access (not_oa) ↩ ↩2

  8. doi:10.3390/molecules28030969 · Lampsas S, Xenou M, Oikonomou E et al. · Molecules 2023 · review · n=N/A · model: human · OxPL-binding mechanism, fibrinolysis inhibition, ECM-binding atherogenicity, endothelial dysfunction · 125 citations; locally available at ↩ ↩2 ↩3

  9. doi:10.1161/circulationaha.124.069210 · Greco A, Capodanno D et al. · Circulation 2025 · review · n=N/A · model: human · therapeutic landscape for Lp(a)-lowering drugs: ASO, siRNA, oral small molecule, gene editing overview; PCSK9i ~25% reduction confirmed · 43 citations; closed-access (not_oa); not PDF-verified ↩ ↩2

  10. doi:10.1016/j.phrs.2026.108178 · Wu AX, Wang XJ, Zhao C, Hu JQ et al. · Pharmacological Research 2026 (May, Vol. 227) · meta-analysis (network) · n=7,715 (25 RCTs) · model: human · olpasiran −92.1% (95% CI −100.1 to −84.0%), zerlasiran −80.6% (95% CI −87.7 to −73.5%), muvalaplin −76.8% (95% CI −90.3 to −63.2%), pelacarsen −54.2% (95% CI −72.2 to −36.2%) Lp(a) reduction; siRNA therapies showed greatest reductions · DOI confirmed in archive but download not yet available (too new); PMID 41937094 ↩

Graph View

Backlinks